BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Megna M, Napolitano M, Fabbrocini G. May IL-17 have a role in COVID-19 infection? Med Hypotheses 2020;140:109749. [PMID: 32339777 DOI: 10.1016/j.mehy.2020.109749] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang M, Yu B, Wang J, Wang Y, Liang L. Exploring the role of Xingren on COVID ‐19 based on network pharmacology and molecular docking. Journal of Food Biochemistry. [DOI: 10.1111/jfbc.14363] [Reference Citation Analysis]
2 Ahmed Mostafa G, Mohamed Ibrahim H, Al Sayed Shehab A, Mohamed Magdy S, Aboabdoun Soliman N, Fathy El-sherif D. Up-regulated serum levels of interleukin (IL)-17A and IL-22 in Egyptian pediatric patients with COVID-19 and MIS-C: Relation to the disease outcome. Cytokine 2022;154:155870. [DOI: 10.1016/j.cyto.2022.155870] [Reference Citation Analysis]
3 Montazersaheb S, Hosseiniyan Khatibi SM, Hejazi MS, Tarhriz V, Farjami A, Ghasemian Sorbeni F, Farahzadi R, Ghasemnejad T. COVID-19 infection: an overview on cytokine storm and related interventions. Virol J 2022;19:92. [PMID: 35619180 DOI: 10.1186/s12985-022-01814-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Elahi S. Hematopoietic responses to SARS-CoV-2 infection. Cell Mol Life Sci 2022;79. [DOI: 10.1007/s00018-022-04220-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Shukla N, Prasad A, Kanga U, Suravajhala R, Nigam VK, Kishor PBK, Polavarapu R, Chaubey G, Singh KK, Suravajhala P. SARS-CoV-2 transgressing LncRNAs uncovers the known unknowns. Physiol Genomics 2021;53:433-40. [PMID: 34492207 DOI: 10.1152/physiolgenomics.00075.2021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Yaneske E, Zampieri G, Bertoldi L, Benvenuto G, Angione C. Genome-scale metabolic modelling of SARS-CoV-2 in cancer cells reveals an increased shift to glycolytic energy production. FEBS Lett 2021;595:2350-65. [PMID: 34409594 DOI: 10.1002/1873-3468.14180] [Reference Citation Analysis]
7 Maione F, Casillo GM, Raucci F, Salvatore C, Ambrosini G, Costa L, Scarpa R, Caso F, Bucci M. Interleukin-17A (IL-17A): A silent amplifier of COVID-19. Biomed Pharmacother 2021;142:111980. [PMID: 34364043 DOI: 10.1016/j.biopha.2021.111980] [Reference Citation Analysis]
8 Islam MB, Chowdhury UN, Nain Z, Uddin S, Ahmed MB, Moni MA. Identifying molecular insight of synergistic complexities for SARS-CoV-2 infection with pre-existing type 2 diabetes. Comput Biol Med 2021;136:104668. [PMID: 34340124 DOI: 10.1016/j.compbiomed.2021.104668] [Reference Citation Analysis]
9 Avdeev SN, Trushenko NV, Tsareva NA, Yaroshetskiy AI, Merzhoeva ZM, Nuralieva GS, Nekludova GV, Chikina SY, Gneusheva TY, Suvorova OA, Shmidt AE. Anti-IL-17 monoclonal antibodies in hospitalized patients with severe COVID-19: A pilot study. Cytokine 2021;146:155627. [PMID: 34237556 DOI: 10.1016/j.cyto.2021.155627] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Thatiparthi A, Martin A, Liu J, Egeberg A, Wu JJ. Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review. Am J Clin Dermatol 2021;22:425-42. [PMID: 33861409 DOI: 10.1007/s40257-021-00603-w] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 14.0] [Reference Citation Analysis]
11 Wilk AJ, Lee MJ, Wei B, Parks B, Pi R, Martínez-Colón GJ, Ranganath T, Zhao NQ, Taylor S, Becker W, Jimenez-Morales D, Blomkalns AL, O'Hara R, Ashley EA, Nadeau KC, Yang S, Holmes S, Rabinovitch M, Rogers AJ, Greenleaf WJ, Blish CA; Stanford COVID-19 Biobank. Multi-omic profiling reveals widespread dysregulation of innate immunity and hematopoiesis in COVID-19. J Exp Med 2021;218:e20210582. [PMID: 34128959 DOI: 10.1084/jem.20210582] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
12 Rawat P, Sharma D, Srivastava A, Janakiraman V, Gromiha MM. Exploring antibody repurposing for COVID-19: beyond presumed roles of therapeutic antibodies. Sci Rep 2021;11:10220. [PMID: 33986382 DOI: 10.1038/s41598-021-89621-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Maslennikov R, Ivashkin V, Vasilieva E, Chipurik M, Semikova P, Semenets V, Russkova T, Levshina A, Grigoriadis D, Magomedov S, Efremova I, Dzhakhaya N. Interleukin 17 antagonist netakimab is effective and safe in the new coronavirus infection (COVID-19). Eur Cytokine Netw 2021;32:8-14. [PMID: 34346869 DOI: 10.1684/ecn.2021.0463] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
14 Generali D, Bosio G, Malberti F, Cuzzoli A, Testa S, Romanini L, Fioravanti A, Morandini A, Pianta L, Giannotti G, Viola EM, Giorgi-Pierfranceschi M, Foramitti M, Tira RA, Zangrandi I, Chiodelli G, Machiavelli A, Cappelletti MR, Giossi A, De Giuli V, Costanzi C, Campana C, Bernocchi O, Sirico M, Zoncada A, Molteni A, Venturini S, Giudici F, Scaltriti M, Pan A. Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study. Int J Infect Dis 2021;104:433-40. [PMID: 33385581 DOI: 10.1016/j.ijid.2020.12.073] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
15 Luban J, Sattler RA, Mühlberger E, Graci JD, Cao L, Weetall M, Trotta C, Colacino JM, Bavari S, Strambio-De-Castillia C, Suder EL, Wang Y, Soloveva V, Cintron-Lue K, Naryshkin NA, Pykett M, Welch EM, O'Keefe K, Kong R, Goodwin E, Jacobson A, Paessler S, Peltz SW. The DHODH inhibitor PTC299 arrests SARS-CoV-2 replication and suppresses induction of inflammatory cytokines. Virus Res 2021;292:198246. [PMID: 33249060 DOI: 10.1016/j.virusres.2020.198246] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
16 Hussen J, Kandeel M, Hemida MG, Al-Mubarak AIA. Antibody-Based Immunotherapeutic Strategies for COVID-19. Pathogens. 2020;9. [PMID: 33167401 DOI: 10.3390/pathogens9110917] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
17 Carissimo G, Xu W, Kwok I, Abdad MY, Chan YH, Fong SW, Puan KJ, Lee CY, Yeo NK, Amrun SN, Chee RS, How W, Chan S, Fan BE, Andiappan AK, Lee B, Rötzschke O, Young BE, Leo YS, Lye DC, Renia L, Ng LG, Larbi A, Ng LF. Whole blood immunophenotyping uncovers immature neutrophil-to-VD2 T-cell ratio as an early marker for severe COVID-19. Nat Commun 2020;11:5243. [PMID: 33067472 DOI: 10.1038/s41467-020-19080-6] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 21.0] [Reference Citation Analysis]
18 Shojaeefar E, Malih N, Rezaei N. The possible double-edged sword effects of vitamin D on COVID-19: A hypothesis. Cell Biol Int 2021;45:54-7. [PMID: 32990980 DOI: 10.1002/cbin.11469] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
19 Cacciapuoti S, De Rosa A, Gelzo M, Megna M, Raia M, Pinchera B, Pontarelli A, Scotto R, Scala E, Scarano F, Scalia G, Castaldo G, Fabbrocini G, Gentile I, Parrella R. Immunocytometric analysis of COVID patients: A contribution to personalized therapy? Life Sci 2020;261:118355. [PMID: 32871183 DOI: 10.1016/j.lfs.2020.118355] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
20 Leija-Martínez JJ, Huang F, Del-Río-Navarro BE, Sanchéz-Muñoz F, Muñoz-Hernández O, Giacoman-Martínez A, Hall-Mondragon MS, Espinosa-Velazquez D. IL-17A and TNF-α as potential biomarkers for acute respiratory distress syndrome and mortality in patients with obesity and COVID-19. Med Hypotheses 2020;144:109935. [PMID: 32795834 DOI: 10.1016/j.mehy.2020.109935] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
21 Luban J, Sattler R, Mühlberger E, Graci JD, Cao L, Weetall M, Trotta C, Colacino JM, Bavari S, Strambio-De-Castillia C, Suder EL, Wang Y, Soloveva V, Cintron-Lue K, Naryshkin NA, Pykett M, Welch EM, O'Keefe K, Kong R, Goodwin E, Jacobson A, Paessler S, Peltz S. The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines. bioRxiv 2020:2020. [PMID: 32793904 DOI: 10.1101/2020.08.05.238394] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
22 Ohadian Moghadam S. A Review on Currently Available Potential Therapeutic Options for COVID-19. Int J Gen Med 2020;13:443-67. [PMID: 32801840 DOI: 10.2147/IJGM.S263666] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
23 Foti R, Amato G, Visalli E. SARS-CoV-2 infection in a psoriatic arthritis patient treated with IL-17 inhibitor. Med Hypotheses 2020;144:110040. [PMID: 32744241 DOI: 10.1016/j.mehy.2020.110040] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Coskun Benlidayi I, Kurtaran B, Tirasci E, Guzel R. Coronavirus disease 2019 (COVID-19) in a patient with ankylosing spondylitis treated with secukinumab: a case-based review. Rheumatol Int 2020;40:1707-16. [PMID: 32591970 DOI: 10.1007/s00296-020-04635-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 7.5] [Reference Citation Analysis]
25 Napolitano M, Patruno C, Ruggiero A, Nocerino M, Fabbrocini G. Safety of dupilumab in atopic patients during COVID-19 outbreak. Journal of Dermatological Treatment. [DOI: 10.1080/09546634.2020.1771257] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
26 Galluzzo M, Tofani L, Bianchi L, Talamonti M. Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era. Expert Opinion on Biological Therapy 2020;20:829-30. [DOI: 10.1080/14712598.2020.1779217] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
27 Dalamaga M, Karampela I, Mantzoros CS. Commentary: Phosphodiesterase 4 inhibitors as potential adjunct treatment targeting the cytokine storm in COVID-19. Metabolism 2020;109:154282. [PMID: 32497535 DOI: 10.1016/j.metabol.2020.154282] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 15.5] [Reference Citation Analysis]
28 [DOI: 10.1101/2020.12.18.423363] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]